Anzeige
❌
Mehr »
Mittwoch, 07.10.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
269 Leser
Artikel bewerten:
(1)

CeCors, Inc.: PsyKey, Inc., Achieves Key Revenue Milestone With Purchase Order Of Its Functional Mushroom Products

CARSON CITY, NV / ACCESSWIRE / January 12, 2022 / CECORS, INC. (OTC PINK:CEOS) ("CeCors" or the "Company "), through its wholly-owned subsidiary PsyKey Inc. is pleased to announce its first purchase order in the amount of $50,000.00 of its functional mushroom-infused coffee line, from innovative marketing firm "Union Marketing."

"This purchase order demonstrates the dedicated work our team has put into not only developing tasty functional coffees but also to our desire for PsyKey's products to stand out and be noticed. We are confident this purchase order will be the first of many to go in line with our nearing e-commerce launch. These steps and milestones will help us to meet our goal of generating ongoing revenue, and working toward getting the shell status removed from the Company." Said Amar Bhatal, President of CeCors, Inc.

PsyKey's functional mushroom-infused coffee is created by combining the highest quality, 100% fair trade organic Arabica coffee beans with powerful functional mushrooms, that have been used and consumed for thousands of years. These mushrooms provide a functional benefit to your great-tasting cup of coffee. Used in eastern traditional medicine for thousands of years and said to promote a stronger memory and sharper focus to boost the immune system and increase recovery times, functional mushrooms will truly help optimize your routine.

"What stemmed from a tenant/landlord relationship has now blossomed into an exciting new opportunity. We have had the opportunity to try some of the upcoming products and were very impressed. We believe this is an opportunity for us to develop a subscription model with PsyKey for our over 750,000 members and their families. The functionality of the products is exciting especially when looking at boosting workplace productivity and employee satisfaction." Said Tim Hirasawa Chief Financial Officer of Union Marketing.

Union Marketing

Union Marketing is a creative marketing firm focused on BRINGING INNOVATION TO UNIONS. We assist unions and associations alike in building successful promotional campaigns and modernizing their communications through innovative products and services.

Unionized since 2013, our staff have a unique understanding of union culture and issues surrounding the labour movement. Through this understanding, we are able to provide clients with the services that are most effective in cultivating a thriving membership.

www.unionmarketing.ca

About PsyKey, Inc.

PsyKey, Inc specializes in the development and commercialization of mycology-based entheogenic, adaptogenic, and nootropic ingredients and formulations. From functional to psychedelic PsyKey believes in the magic of mushrooms.

As part of our optimal wellness strategy, PsyKey understands the importance of access to support services and healthcare professionals and is engaged in the development of tools that will aid in removing barriers and providing inclusivity.

For further information:

Publicly traded company (OTC PINK:CEOS)
Website: www.psykeyworld.com
E-mail: info@psykeyworld.com
Follow us on Twitter: https://twitter.com/PsyKeyworld

Forward-Looking Statements:

Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency, and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: CeCors, Inc.



View source version on accesswire.com:
https://www.accesswire.com/683102/PsyKey-Inc-Achieves-Key-Revenue-Milestone-With-Purchase-Order-Of-Its-Functional-Mushroom-Products

© 2022 ACCESS Newswire
KI-Euphorie kippt - Bei diesen 5 Aktien droht der Crash!
Drei Jahre lang kannten KI-Aktien fast nur eine Richtung: nach oben. Billionenschwere Investitionspläne von Alphabet, Amazon, Meta und Microsoft haben Halbleiter- und Infrastrukturwerte auf immer neue Höhen getrieben. Doch jetzt bekommt die Erfolgsstory gefährliche Risse.

Steigende Anleiherenditen verteuern die Finanzierung, während die gewaltigen KI-Ausgaben zunehmend nicht mehr aus den laufenden Cashflows bezahlt werden können. Gleichzeitig zeigen günstigere chinesische Modelle, dass leistungsfähige KI womöglich mit deutlich weniger Rechenleistung auskommt. Damit wächst die Gefahr, dass heute für Milliarden errichtete Kapazitäten morgen nicht die erhofften Renditen liefern.

Für Anleger könnte das zum Problem werden. Denn treffen steigende Finanzierungskosten auf Überkapazitäten und enttäuschende Cashflows, geraten gerade hoch bewertete KI-Profiteure schnell unter Druck. Aus den größten Gewinnern der vergangenen Jahre könnten so die größten Verlierer der nächsten Korrektur werden.

In unserem aktuellen Spezialreport zeigen wir 5 Aktien, bei denen das Chance-Risiko-Verhältnis jetzt besonders gefährlich erscheint – und bei denen Anleger genauer hinschauen sollten.

Jetzt den kostenlosen Report sichern – bevor die KI-Euphorie ihren nächsten Realitätstest erlebt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.